Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Dose-Response-Time Data Analysis: An Underexploited Trinity.

Gabrielsson J, Andersson R, Jirstrand M, Hjorth S.

Pharmacol Rev. 2019 Jan;71(1):89-122. doi: 10.1124/pr.118.015750. Review.

PMID:
30587536
2.

Challenging the dose-response-time data approach: Analysis of a complex system.

Andersson R, Jirstrand M, Almquist J, Gabrielsson J.

Eur J Pharm Sci. 2019 Feb 1;128:250-269. doi: 10.1016/j.ejps.2018.11.015. Epub 2018 Nov 17.

PMID:
30453011
3.

Michaelis-Menten from an In Vivo Perspective: Open Versus Closed Systems.

Gabrielsson J, Peletier LA.

AAPS J. 2018 Sep 12;20(6):102. doi: 10.1208/s12248-018-0256-z.

PMID:
30209711
4.

Lost in translation: What's in an EC50? Innovative PK/PD reasoning in the drug development context.

Gabrielsson J, Peletier LA, Hjorth S.

Eur J Pharmacol. 2018 Sep 15;835:154-161. doi: 10.1016/j.ejphar.2018.07.037. Epub 2018 Jul 21.

PMID:
30036536
5.

Evaluation and translation of combination therapies in oncology - A quantitative approach.

Cardilin T, Almquist J, Jirstrand M, Gabrielsson J.

Eur J Pharmacol. 2018 Sep 5;834:327-336. doi: 10.1016/j.ejphar.2018.07.041. Epub 2018 Jul 20. Review.

6.

New Equilibrium Models of Drug-Receptor Interactions Derived from Target-Mediated Drug Disposition.

Peletier LA, Gabrielsson J.

AAPS J. 2018 May 14;20(4):69. doi: 10.1208/s12248-018-0221-x.

PMID:
29761231
7.

Model-Based Evaluation of Radiation and Radiosensitizing Agents in Oncology.

Cardilin T, Almquist J, Jirstrand M, Zimmermann A, El Bawab S, Gabrielsson J.

CPT Pharmacometrics Syst Pharmacol. 2018 Jan;7(1):51-58. doi: 10.1002/psp4.12268. Epub 2017 Dec 14.

8.

In vivo potency revisited - Keep the target in sight.

Gabrielsson J, Peletier LA, Hjorth S.

Pharmacol Ther. 2018 Apr;184:177-188. doi: 10.1016/j.pharmthera.2017.10.011. Epub 2017 Oct 10. Review.

PMID:
29024741
9.

Impact of mathematical pharmacology on practice and theory: four case studies.

Peletier LA, Gabrielsson J.

J Pharmacokinet Pharmacodyn. 2018 Feb;45(1):3-21. doi: 10.1007/s10928-017-9539-8. Epub 2017 Sep 7.

10.

Modeling of free fatty acid dynamics: insulin and nicotinic acid resistance under acute and chronic treatments.

Andersson R, Kroon T, Almquist J, Jirstrand M, Oakes ND, Evans ND, Chappel MJ, Gabrielsson J.

J Pharmacokinet Pharmacodyn. 2017 Jun;44(3):203-222. doi: 10.1007/s10928-017-9512-6. Epub 2017 Feb 21.

11.

Pharmacokinetic Steady-States Highlight Interesting Target-Mediated Disposition Properties.

Gabrielsson J, Peletier LA.

AAPS J. 2017 May;19(3):772-786. doi: 10.1208/s12248-016-0031-y. Epub 2017 Jan 31.

PMID:
28144911
12.

Erratum to: Tumor Static Concentration Curves in Combination Therapy.

Cardilin T, Almquist J, Jirstand M, Soselly A, Amendt C, El Bawab S, Gabrielsson J.

AAPS J. 2017 Mar;19(2):596. doi: 10.1208/s12248-016-0035-7. No abstract available.

PMID:
28058529
13.

Nicotinic acid timed to feeding reverses tissue lipid accumulation and improves glucose control in obese Zucker rats[S].

Kroon T, Baccega T, Olsén A, Gabrielsson J, Oakes ND.

J Lipid Res. 2017 Jan;58(1):31-41. doi: 10.1194/jlr.M068395. Epub 2016 Nov 15.

14.

Tumor Static Concentration Curves in Combination Therapy.

Cardilin T, Almquist J, Jirstrand M, Sostelly A, Amendt C, El Bawab S, Gabrielsson J.

AAPS J. 2017 Mar;19(2):456-467. doi: 10.1208/s12248-016-9991-1. Epub 2016 Sep 28. Erratum in: AAPS J. 2017 Mar;19(2):596.

PMID:
27681102
15.

Mixture dynamics: Combination therapy in oncology.

Gabrielsson J, Gibbons FD, Peletier LA.

Eur J Pharm Sci. 2016 Jun 10;88:132-46. doi: 10.1016/j.ejps.2016.02.020. Epub 2016 Apr 3.

PMID:
27050307
16.

Mathematical modeling and simulation in animal health. Part I: Moving beyond pharmacokinetics.

Riviere JE, Gabrielsson J, Fink M, Mochel J.

J Vet Pharmacol Ther. 2016 Jun;39(3):213-23. doi: 10.1111/jvp.12278. Epub 2015 Nov 22. Review.

PMID:
26592724
17.

A quantitative approach to analysing cortisol response in the horse.

Ekstrand C, Ingvast-Larsson C, Olsén L, Hedeland M, Bondesson U, Gabrielsson J.

J Vet Pharmacol Ther. 2016 Jun;39(3):255-63. doi: 10.1111/jvp.12276. Epub 2015 Nov 6.

PMID:
26542753
18.

Pattern Recognition in Pharmacodynamic Data Analysis.

Gabrielsson J, Hjorth S.

AAPS J. 2016 Jan;18(1):64-91. doi: 10.1208/s12248-015-9842-5. Epub 2015 Nov 5. Review.

PMID:
26542613
19.

Dose-response-time modelling: Second-generation turnover model with integral feedback control.

Andersson R, Jirstrand M, Peletier L, Chappell MJ, Evans ND, Gabrielsson J.

Eur J Pharm Sci. 2016 Jan 1;81:189-200. doi: 10.1016/j.ejps.2015.10.018. Epub 2015 Oct 31.

PMID:
26529383
20.

Pattern Recognition in Pharmacokinetic Data Analysis.

Gabrielsson J, Meibohm B, Weiner D.

AAPS J. 2016 Jan;18(1):47-63. doi: 10.1208/s12248-015-9817-6. Epub 2015 Sep 3. Review.

21.

Dosing profile profoundly influences nicotinic acid's ability to improve metabolic control in rats.

Kroon T, Kjellstedt A, Thalén P, Gabrielsson J, Oakes ND.

J Lipid Res. 2015 Sep;56(9):1679-90. doi: 10.1194/jlr.M058149. Epub 2015 Jul 13.

22.

Tissue uptake, distribution and elimination of (14)C-PFOA in zebrafish (Danio rerio).

Ulhaq M, Sundström M, Larsson P, Gabrielsson J, Bergman Å, Norrgren L, Örn S.

Aquat Toxicol. 2015 Jun;163:148-57. doi: 10.1016/j.aquatox.2015.04.003. Epub 2015 Apr 3.

PMID:
25897689
23.

Mixed Effects Modeling Using Stochastic Differential Equations: Illustrated by Pharmacokinetic Data of Nicotinic Acid in Obese Zucker Rats.

Leander J, Almquist J, Ahlström C, Gabrielsson J, Jirstrand M.

AAPS J. 2015 May;17(3):586-96. doi: 10.1208/s12248-015-9718-8. Epub 2015 Feb 19.

24.

Modeling and design of challenge tests: Inflammatory and metabolic biomarker study examples.

Gabrielsson J, Hjorth S, Vogg B, Harlfinger S, Gutierrez PM, Peletier L, Pehrson R, Davidsson P.

Eur J Pharm Sci. 2015 Jan 25;67:144-159. doi: 10.1016/j.ejps.2014.11.006. Epub 2014 Nov 28.

PMID:
25435491
25.

Modeling energy intake by adding homeostatic feedback and drug intervention.

Gennemark P, Hjorth S, Gabrielsson J.

J Pharmacokinet Pharmacodyn. 2015 Feb;42(1):79-96. doi: 10.1007/s10928-014-9399-4. Epub 2014 Nov 12.

PMID:
25388764
26.

Plasma concentration-dependent suppression of endogenous hydrocortisone in the horse after intramuscular administration of dexamethasone-21-isonicotinate.

Ekstrand C, Bondesson U, Gabrielsson J, Hedeland M, Kallings P, Olsén L, Ingvast-Larsson C.

J Vet Pharmacol Ther. 2015 Jun;38(3):235-42. doi: 10.1111/jvp.12175. Epub 2014 Nov 3.

PMID:
25366540
27.

Joint feedback analysis modeling of nonesterified fatty acids in obese Zucker rats and normal Sprague-Dawley rats after different routes of administration of nicotinic acid.

Tapani S, Almquist J, Leander J, Ahlström C, Peletier LA, Jirstrand M, Gabrielsson J.

J Pharm Sci. 2014 Aug;103(8):2571-84. doi: 10.1002/jps.24077. Epub 2014 Jul 1.

28.

Dose-response-time data analysis involving nonlinear dynamics, feedback and delay.

Gabrielsson J, Peletier LA.

Eur J Pharm Sci. 2014 Aug 1;59:36-48. doi: 10.1016/j.ejps.2014.04.007. Epub 2014 Apr 19.

PMID:
24751673
29.

Maxsim2 - Real-time interactive simulations for computer-assisted teaching of pharmacokinetics and pharmacodynamics.

Gabrielsson J, Andersson K, Tobin G, Ingvast-Larsson C, Jirstrand M.

Comput Methods Programs Biomed. 2014 Mar;113(3):815-29. doi: 10.1016/j.cmpb.2013.12.006. Epub 2013 Dec 25.

30.

A modeling approach for compounds affecting body composition.

Gennemark P, Jansson-Löfmark R, Hyberg G, Wigstrand M, Kakol-Palm D, Håkansson P, Hovdal D, Brodin P, Fritsch-Fredin M, Antonsson M, Ploj K, Gabrielsson J.

J Pharmacokinet Pharmacodyn. 2013 Dec;40(6):651-67. doi: 10.1007/s10928-013-9337-x. Epub 2013 Oct 25.

PMID:
24158456
31.

Feedback modeling of non-esterified fatty acids in obese Zucker rats after nicotinic acid infusions.

Ahlström C, Kroon T, Peletier LA, Gabrielsson J.

J Pharmacokinet Pharmacodyn. 2013 Dec;40(6):623-38. doi: 10.1007/s10928-013-9335-z. Epub 2013 Oct 10.

PMID:
24114415
32.

Mixture dynamics: dual action of inhibition and stimulation.

Gabrielsson J, Peletier LA.

Eur J Pharm Sci. 2013 Oct 9;50(2):215-26. doi: 10.1016/j.ejps.2013.06.010. Epub 2013 Jul 4.

PMID:
23831518
33.

Challenges of a mechanistic feedback model describing nicotinic acid-induced changes in non-esterified fatty acids in rats.

Ahlström C, Peletier LA, Gabrielsson J.

J Pharmacokinet Pharmacodyn. 2013 Aug;40(4):497-512. doi: 10.1007/s10928-013-9325-1. Epub 2013 Jul 4.

PMID:
23824920
34.

Animal Health Modeling & Simulation Society: a new society promoting model-based approaches in veterinary pharmacology.

Mochel JP, Gabrielsson J, Collard W, Fink M, Gehring R, Laffont C, Liu Y, Martin-Jimenez T, Pelligand L, Steimer JL, Toutain PL, Whittem T, Riviere J.

J Vet Pharmacol Ther. 2013 May 29. doi: 10.1111/jvp.12060. [Epub ahead of print]

PMID:
23713757
35.

Non-compartmental analysis.

Gabrielsson J, Weiner D.

Methods Mol Biol. 2012;929:377-89.

PMID:
23007438
36.

Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification.

Peletier LA, Gabrielsson J.

J Pharmacokinet Pharmacodyn. 2012 Oct;39(5):429-51. doi: 10.1007/s10928-012-9260-6. Epub 2012 Aug 1.

37.

Quantitative analysis of rate and extent of tolerance of biomarkers: application to nicotinic acid-induced changes in non-esterified fatty acids in rats.

Ahlström C, Peletier LA, Gabrielsson J.

Eur J Pharm Sci. 2011 Oct 9;44(3):250-64. doi: 10.1016/j.ejps.2011.08.005. Epub 2011 Aug 11.

PMID:
21856416
38.

Translational neuropharmacology and the appropriate and effective use of animal models.

Green AR, Gabrielsson J, Fone KC.

Br J Pharmacol. 2011 Oct;164(4):1041-3. doi: 10.1111/j.1476-5381.2011.01361.x.

39.

Pharmacodynamic-pharmacokinetic integration as a guide to medicinal chemistry.

Gabrielsson J, Fjellström O, Ulander J, Rowley M, Van Der Graaf PH.

Curr Top Med Chem. 2011;11(4):404-18. Review.

PMID:
21320067
40.

Diagnostic properties of metabolic perturbations in rheumatoid arthritis.

Madsen RK, Lundstedt T, Gabrielsson J, Sennbro CJ, Alenius GM, Moritz T, Rantapää-Dahlqvist S, Trygg J.

Arthritis Res Ther. 2011 Feb 8;13(1):R19. doi: 10.1186/ar3243.

41.

Feedback modeling of non-esterified fatty acids in rats after nicotinic acid infusions.

Ahlström C, Peletier LA, Jansson-Löfmark R, Gabrielsson J.

J Pharmacokinet Pharmacodyn. 2011 Feb;38(1):1-24. doi: 10.1007/s10928-010-9172-2. Epub 2010 Nov 4.

42.

Optimising in vivo pharmacology studies--Practical PKPD considerations.

Gabrielsson J, Green AR, Van der Graaf PH.

J Pharmacol Toxicol Methods. 2010 Mar-Apr;61(2):146-56. doi: 10.1016/j.vascn.2010.02.002. Epub 2010 Feb 11. Review.

PMID:
20153442
43.

A novel bone conduction implant (BCI): engineering aspects and pre-clinical studies.

Håkansson B, Reinfeldt S, Eeg-Olofsson M, Ostli P, Taghavi H, Adler J, Gabrielsson J, Stenfelt S, Granström G.

Int J Audiol. 2010 Mar;49(3):203-15. doi: 10.3109/14992020903264462.

PMID:
20105095
44.

Pharmacokinetic-pharmacodynamic reasoning in drug discovery and early development.

Van Der Graaf PH, Gabrielsson J.

Future Med Chem. 2009 Nov;1(8):1371-4. doi: 10.4155/fmc.09.124. No abstract available.

PMID:
21426051
45.

Turnover modeling of non-esterified fatty acids in rats after multiple intravenous infusions of nicotinic acid.

Isaksson C, Gabrielsson J, Wallenius K, Peletier LA, Toreson H.

Dose Response. 2009 Apr 8;7(3):247-69. doi: 10.2203/dose-response.08-028.Isaksson.

46.

Dynamics of target-mediated drug disposition.

Peletier LA, Gabrielsson J.

Eur J Pharm Sci. 2009 Dec 8;38(5):445-64. doi: 10.1016/j.ejps.2009.09.007. Epub 2009 Sep 26.

PMID:
19786099
47.

Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.

Gabrielsson J, Green AR.

J Pharmacol Exp Ther. 2009 Dec;331(3):767-74. doi: 10.1124/jpet.109.157172. Epub 2009 Sep 24. Review.

48.

Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations.

Gabrielsson J, Dolgos H, Gillberg PG, Bredberg U, Benthem B, Duker G.

Drug Discov Today. 2009 Apr;14(7-8):358-72. doi: 10.1016/j.drudis.2008.12.011. Epub 2009 Jan 20. Review.

PMID:
19162219
49.

Nonlinear turnover models for systems with physiological limits.

Peletier LA, Gabrielsson J.

Eur J Pharm Sci. 2009 Apr 11;37(1):11-26. doi: 10.1016/j.ejps.2008.12.012. Epub 2008 Dec 30.

PMID:
19159683
50.

MDMA: on the translation from rodent to human dosing.

Green AR, Gabrielsson J, Marsden CA, Fone KC.

Psychopharmacology (Berl). 2009 Jun;204(2):375-8. doi: 10.1007/s00213-008-1453-8. Epub 2009 Jan 13. No abstract available.

PMID:
19139850

Supplemental Content

Loading ...
Support Center